These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 37899178)

  • 1. [Treatment strategies for follicular lymphoma].
    Fukuhara N
    Rinsho Ketsueki; 2023; 64(9):1019-1025. PubMed ID: 37899178
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
    Plosker GL; Figgitt DP
    Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Updates in treatment strategies for follicular lymphoma].
    Fukuhara N
    Rinsho Ketsueki; 2020; 61(9):1252-1258. PubMed ID: 33162523
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current approaches and future perspectives for advanced-stage follicular lymphoma with a low tumor burden.
    Fukuhara N; Ishizawa K
    Jpn J Clin Oncol; 2019 Apr; 49(4):306-310. PubMed ID: 30715424
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rituximab: a review of its use in chronic lymphocytic leukaemia, low-grade or follicular lymphoma and diffuse large B-cell lymphoma.
    Keating GM
    Drugs; 2010 Jul; 70(11):1445-76. PubMed ID: 20614951
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The current therapeutic landscape for follicular lymphoma].
    Kobayashi T
    Rinsho Ketsueki; 2021; 62(8):1070-1076. PubMed ID: 34497193
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Standard treatment and future perspectives for follicular lymphoma].
    Kameoka Y
    Rinsho Ketsueki; 2022; 63(9):1135-1144. PubMed ID: 36198539
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chlorambucil-rituximab as first-line therapy in patients affected by follicular non-Hodgkin's lymphoma: a retrospective single-centre study.
    Martinelli G; Montoro J; Vanazzi A; Andreola G; Liptrott S; Radice D; Negri M; Preda L; Pruneri G; Laszlo D
    Hematol Oncol; 2015 Dec; 33(4):129-35. PubMed ID: 25047267
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Follicular lymphoma: The long and winding road leading to your cure?
    Gordon MJ; Smith MR; Nastoupil LJ
    Blood Rev; 2023 Jan; 57():100992. PubMed ID: 35908982
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Follicular lymphoma: recent advances].
    Ando K
    Rinsho Ketsueki; 2018; 59(10):2104-2108. PubMed ID: 30305515
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Front-line management of non-Hodgkin lymphoma in Australia. Part 1: follicular lymphoma.
    Trotman J; Cheah CY; Marlton P; Opat S
    Intern Med J; 2019 Apr; 49(4):422-433. PubMed ID: 30230156
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mosunetuzumab and the emerging role of T-cell-engaging therapy in follicular lymphoma.
    Matarasso S; Assouline S
    Future Oncol; 2023 Oct; 19(31):2083-2101. PubMed ID: 37882361
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overall Survival Benefit in Patients With Rituximab-Refractory Indolent Non-Hodgkin Lymphoma Who Received Obinutuzumab Plus Bendamustine Induction and Obinutuzumab Maintenance in the GADOLIN Study.
    Cheson BD; Chua N; Mayer J; Dueck G; Trněný M; Bouabdallah K; Fowler N; Delwail V; Press O; Salles G; Gribben JG; Lennard A; Lugtenburg PJ; Fingerle-Rowson G; Mattiello F; Knapp A; Sehn LH
    J Clin Oncol; 2018 Aug; 36(22):2259-2266. PubMed ID: 29584548
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The therapeutic use of rituximab in non-Hodgkin's lymphoma.
    Marcus R; Hagenbeek A
    Eur J Haematol Suppl; 2007 Jan; (67):5-14. PubMed ID: 17206982
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rituximab therapy for indolent non-Hodgkin's lymphoma.
    Hagenbeek A; Czuczman MS; Ghielmini M; Herold M; Kimby E; Solal-Céligny P; Unterhalt M
    Anticancer Drugs; 2002 Nov; 13 Suppl 2():S11-7. PubMed ID: 12710586
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rituximab Maintenance Strategy in Advanced Follicular Lymphoma: Facts and Controversies.
    Milunović V; Bogeljić Patekar M; Jakubac KM; Mandac Rogulj I; Radić-Krišto D; Planinc-Peraica A; Ostojić Kolonić S
    Acta Clin Croat; 2017 Mar; 56(1):143-156. PubMed ID: 29120553
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increasing treatment options in indolent non-Hodgkin's lymphoma.
    Solal-Céligny P
    Semin Oncol; 2002 Apr; 29(2 Suppl 6):2-6. PubMed ID: 12040527
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial.
    Sehn LH; Chua N; Mayer J; Dueck G; Trněný M; Bouabdallah K; Fowler N; Delwail V; Press O; Salles G; Gribben J; Lennard A; Lugtenburg PJ; Dimier N; Wassner-Fritsch E; Fingerle-Rowson G; Cheson BD
    Lancet Oncol; 2016 Aug; 17(8):1081-1093. PubMed ID: 27345636
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A review of rituximab, the first anti-CD20 monoclonal antibody used in the treatment of B non-Hodgkin's lymphomas.
    Feugier P
    Future Oncol; 2015; 11(9):1327-42. PubMed ID: 25952779
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin's lymphoma.
    Boland A; Bagust A; Hockenhull J; Davis H; Chu P; Dickson R
    Health Technol Assess; 2009 Sep; 13 Suppl 2():41-8. PubMed ID: 19804688
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.